Skip to main content
. 2003 Jul 1;89(1):215–221. doi: 10.1038/sj.bjc.6601029

Figure 5.

Figure 5

CMDB7 inhibits the tumour angiogenesis. Intratumour vascularisation was analysed immunohistologically after labelling of endothelial cells with a specific marker GSL-1. (A) Section of saline-treated (control) tumour and (B) section of tumour treated with 30 mg kg week−1 of CMDB7. (C) Endothelial cell density was evaluated by image analysis of GSL-1-labelled endothelial cells and the results are presented as the mean areas±s.e. (bars) of endothelial cells in the CMDB7-treated and control tumour sections obtained from 10 mice for each group. **, significantly different from control (P<0.001).